Moderna COVID-19 vaccine ‘promises’ an immune response and safety at Stage 1 research

The experimental vaccine against COVID-19, which is being developed by the American company Moderna, was able to elicit an immune response in all volunteers at an early stage of the study. Relevant data is published in the New England Journal of Medicine.

The study showed that some antibodies were produced after a single dose of the vaccine, however, four weeks later a second dose was required, after which the vaccine elicited a strong immune response in all 45 volunteers.

According to Moderna CEO Stephane Bancel, the results are “encouraging and represent an important step forward in the clinical development of mRNA-1273, our candidate for the COVID-19 vaccine.”

The study involved 45 healthy volunteers between the ages of 18 and 55 at Seattle and Emory University in Georgia. Participants in the experiment were given three dose levels of the Moderna vaccine at 25, 100, and 250 micrograms.

On July 27, Moderna is expected to begin a much larger study of the third-stage vaccine trial, which will bring together 30,000 participants in 87 locations.